BRCA2 and cancer: A recent study of our group accessed the prevalence ofthree founder mutations (BRCA1 c.68_69del, BRCA1c.5266dupC - former named as 5382insC, and BRCA2 c.5946del) commonlyidentified in Ashkenazi individuals in a sample of 137 non-Ashkenazi cancer-affectedwomen from Rio de Janeiro and Porto Alegre (all of them fulfilled clinical criteria forHBOC).